PARIS--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced the availability of its Dexcom ONE real-time CGM sensor via reimbursement, in France.

PARIS-（BUSINESS WIRE）-DexCom，Inc。（纳斯达克股票代码：DXCM）是糖尿病患者实时连续血糖监测的全球领导者，今天宣布通过以下方式提供DexCom ONE实时CGM传感器报销，在法国。

Dexcom’s announcement brings the company’s highly researched and studied, real-time CGM technology to half a million more people with diabetes in France. Specifically, access is now secured to the Dexcom ONE sensor for all patients with type 1 and type 2 diabetes, two years and older, who are undergoing intensive insulin therapy (by external pump or >3 injections per day)..

Dexcom的公告将该公司高度研究和研究的实时CGM技术带到法国50万糖尿病患者身上。具体而言，对于正在接受强化胰岛素治疗（通过外部泵或每天>3次注射）的所有1型和2型糖尿病患者，现在可以使用Dexcom ONE传感器。。

The proven accuracy of Dexcom ONE1# allows people to make confident treatment decisions in real-time, without scanning, and as a real-time CGM with alerts, is shown to improve time-in-range significantly more than Flash Glucose Monitoring (isCGM)2§.

Dexcom ONE1＃的经过验证的准确性使人们能够实时做出自信的治疗决策，无需扫描，并且作为带有警报的实时CGM，其显示的时间范围显着超过快速血糖监测（isCGM）2§。

“We believe this is truly exciting news for people living with diabetes in France,” said Gérald Zammit, Country Director of Dexcom France. 'Access to Dexcom real-time CGM sensors is now available to those who live with diabetes, who aren’t necessarily seen as ‘high risk’, but who can still greatly benefit from it.

“我们相信这对法国糖尿病患者来说是一个真正令人兴奋的消息，”法国Dexcom国家主任GéraldZammit说对于那些患有糖尿病的人来说，现在可以使用Dexcom实时CGM传感器，他们不一定被视为“高风险”，但他们仍然可以从中受益匪浅。

The launch of Dexcom ONE in France will help to make real-time CGM accessible to as many patients as possible.”.

Dexcom ONE在法国的推出将有助于使尽可能多的患者能够实时访问CGM“。

Dexcom real-time CGM use is clinically proven to lower HbA1C, reduce hyper- and hypoglycaemia, and increase time in range3-5.

Dexcom实时CGM的使用在临床上被证明可以降低HbA1C，减少高血糖和低血糖，并增加时间范围3-5。

The launch of Dexcom ONE in France means patients now have access to a choice of Dexcom real-time CGM sensors, the Dexcom G6 continues to offer Type 1, high risk, patients industry-leading connectivity through integrations with leading insulin delivery systems and digital health apps.

Dexcom ONE在法国推出意味着患者现在可以使用Dexcom实时CGM传感器的选择，Dexcom G6通过与领先的胰岛素输送系统和数字健康集成，继续提供1型，高风险，患者行业领先的连接应用程序。

§ Results obtained with an rt-CGM with alerts, similar to Dexcom ONE, and compared to Freestyle Libre 1.

§使用带有警报的rt CGM获得的结果，类似于Dexcom ONE，并与Freestyle Libre 1进行比较。

# Results obtained with Dexcom G6, which uses the same applicator and sensor (and algorithm) as Dexcom ONE

#使用与Dexcom ONE相同的施加器和传感器（和算法）的Dexcom G6获得的结果

1 Shah VN, et al. Diabetes Technol Ther. 2018;20(6):428-433. 2 Haskova et al. Diabetes Care. 2020;43(11):2744-2750. 3 Beck, RW, et al. JAMA. 2017;317(4):371-378. 4 Welsh, JB et al. Diabetes Technol Ther. 2019;21(3):128-132. 5. Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.

1 Shah VN等人，《糖尿病技术》。2018年；20（6）：428-433.2 Haskova等人，糖尿病护理。2020年；43（11）：2744-2750.3贝克、R.W.等人。2017年；317（4）：371-378.4威尔士，J.B.等人，《糖尿病技术》。2019年；21（3）：128-132.5。Beck RW等人，Ann Intern Med.2017；167（6）：365-374。